Eli Lilly's diabetes drug Mounjaro has secured a concrete African growth target, with distributor Aspen Pharmacare expecting regional sales to break 2 billion rand, or roughly $124 million, in the year ending June 2027. That target represents only about 1.25% of Lilly's global quarterly Mounjaro sales of $9.94 billion, underscoring that Africa will not yet move Lilly's numbers. However, South Africa's GLP-1 market nearly doubled to 2.8 billion rand over the past year, and Mounjaro's share there rocketed from 15% to 53%. Pending registrations in Kenya and Nigeria could widen Lilly's runway, and early distribution and physician adoption may lock in a lead before the regional market matures. Lilly shares traded at $1,154.24, sitting 24.44% below its GF Value estimate of roughly $1,530.
Eli Lilly and CompanyMounjaro's African expansion and market share growth signal increasing product demand
Chevron CorpAspen expects regional sales to break 2 billion rand, indicating strong demand for its distribution
